Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (3972)	12/21/1997 12:32:00 AM
From: Cacaito	Read Replies (2) \| Respond to of 23519

Vivus will not respond to Goldstein. It is not necessary. They must respond with production and sales. I do not care Goldstein at all. Goldstein works for Zonagen. Goldstein works for HVSF (he does not see a future for Vivus Muse but he sees future in HVSF completely non proven product, not even the type I study from HVSF could be considered real since they "completed" more than a year ago and nothing available, plus the patent is clearly Vivus). Goldstein works for Senetek, he and Padma-Nathan were recently chosen (announcement from the Spain seminar on ED) to conduct the US type III studies for Senetek injectable combination phentolamine/VIP. Needle. Goldstein works for Macrochem, the product is not proven and he sees future in a gel for ED that contain the same PGE1 in Muse. Plus the absorption is a big problem, and once is absorbed a lot of it will go systemic through the skin vessels, which go their way no exactly following the corpora cavernosa vessels (Urologist correct me if I am wrong on this last statement), plus no control in the women side of the equation (probably a problem, probably not). Did Goldstein work for Pfizer before? I do not remember well, but I think so. BigKNY you are right Pfizer could not care less what Barron's do and they are not behind this. Neither they were before when Barron's went after Vivus. I was hoping for a bigger story with details on the production,plant,MCA,FDA,cash,tax but it seems they do not know more than this thread, or they are still working on the next article. My hope from Barron's is a big article like the one they did for Lipo or Zonagen. I will not go to the library for this one.(neither pay the $3) Barron's article will frighten nobody. Everybody knows Goldstein and Padma-Nathan open their mouth against Vivus and they reduced the % of Muse responders (P-M went down as far as 5% in one interview, the same he was claiming more than 80% in viagra). Is Goldstein still doubtful that yohimbine does not work?, he could read the 100 mg dose study just published in the Journal of Urology in November or December issue, from Brazil with no FDA to protect patients from high dose ( this is probably the highest dose used for Yohimbine in a formal study) and the result is clear: same as placebo. Vivus downfall was not viagra, neither Barron's, why did anybody pay $42 for Vivus? viagra was there too, or is it that no institution pay the $30s and above? were only individual investors buying? I doubt that, the big ones were the more upset ones in the CC. And Remember that when the price was going above $33 Vinik was selling, I doubt that individual investors were the only ones accumulating, and at the time all TA indicators were showing acute accumulation usually a sign of institutions buying. Vinik dumped 1 million shares and the price went up. The VP dumped hundreds of thousands and the price was either holding or going up. No fear of viagra, it was fear of the production problem that leak finally at the time of the UK approval, at that time there was no reaction, it was clear only small investors were accumulating at that time. Vivus problem was the production mishandling, and 1000 times worst the timing of the news that is why people will pay a PE of 10 and not a PE of 100. BigKNY3, Goldstein must conduct an academic trial of Muse for you to say that he has "investigated" Muse, otherwise he is not better than anybody else, you can read and I can read whatever is published and we can consult statisticians and clinicians if necessary. He does know about the subject but his po$ition is well known. I think you are not confusing Goldstein(Boston) with Goldberg(Dallas). But in case you were they are not. The article says Goldberg investigated Muse, not Goldstein. BigKNY3, I do share your frustration with the constant tirade of PFE did this or that against Vivus. Pfizer has never attack Vivus in any form but competing with their science (the reverse is also true) I admire your tenacity and faith defending Pfizer (rightly so) on this issue. Congratulations in the recent approval of Trovan, you must be happy. I wish Pfizer exercise their muscle and takeover the tiny Vvus.

To: BigKNY3 who wrote (3972)	12/21/1997 7:02:00 AM
From: James Baker	Read Replies (1) \| Respond to of 23519

ooops BigKNY you have confused the Goldstein and Goldberg mentioned in the article. Still looking for Irwin Goldstein, MD. But even past contract does not tell the entire story. Look at Dr P-N he has worked for several ED companies since landmark NEJM article about MUSE - but now he has very little good to say about MUSE and the % successs fall with every interview. Have the studies changed or has the writer of his paycheck????? <<<James: I always like a research challenge! Dr. Irwin Goldstein has investigated MUSE. In a 1997 issue of Medical Tribune (38 (3):1997) an article "Understanding As Important As Treatment for Erectile Dysfunction" featured an interview with Dr. Irwin Goldstein. It is noted that "Dr. Goldberg, who participated in clinical trials of the device, said many men prefer the MUSE to penile injections." BigKNY3>>>